Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation. (June 2015)

• Record Type: Journal Article
• Authors: Sánchez-Lázaro, Ignacio; Herrero, María José; Jordán-De Luna, Consuelo; Bosó, Virginia; Almenar, Luis; Rojas, Luis; Martínez-Dolz, Luis; Megías-Vericat, Juan E; Sendra, Luis; Miguel, Antonio; Poveda, José L; Aliño, Salvador F
• Is Part Of: Pharmacogenomics. Volume 16:Number 9(2015)
• Page Start: 971
• Page End: 979
• Publication Date: 2015-06
• Subjects: cyclosporine -- graft rejection -- infection -- polymorphism -- renal function -- tacrolimus; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.15.39
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: Studying the possible influence of SNPs on efficacy and safety of calcineurin inhibitors upon heart transplantation.Materials & methods: In 60 heart transplant patients treated with tacrolimus or cyclosporine, we studied a panel of 36 SNPs correlated with a series of clinical parameters during the first post-transplantation year.Results: The presence of serious infections was correlated to ABCB1 rs1128503 (p = 0.012), CC genotype reduced the probability of infections being also associated with lower blood cyclosporine concentrations. Lower renal function levels were found in patients with rs9282564 AG (p = 0.003), related to higher blood cyclosporine blood levels. A tendency toward increased graft rejection (p = 0.05) was correlated to rs2066844 CC in NOD2/CARD15, a gene related to lymphocyte activation.Conclusion: Pharmacogenetics can help identify patients at increased risk of clinical complications. Original submitted 30 January 2015; revision submitted 27 March 2015